|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:atccode
|
C02 KX01
|
|
gptkbp:brand
|
gptkb:Opsumit
|
|
gptkbp:chemical_formula
|
C23 H30 N2 O4 S
|
|
gptkbp:class
|
gptkb:Bastiladon
antihypertensive
|
|
gptkbp:clinical_trial
|
Phase III
GRIPHON
MRE-009
SERAPHIN
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
|
|
gptkbp:developed_by
|
gptkb:Actelion_Pharmaceuticals
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:duration
|
long-term
|
|
gptkbp:effective_date
|
2013-10-29
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
film-coated tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
macitentan
|
|
gptkbp:indication
|
improving exercise capacity
|
|
gptkbp:interacts_with
|
nitrates
CYP3 A4 inducers
CYP3 A4 inhibitors
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_a_guide_for
|
NICE guidelines
ESC/ ERS guidelines
|
|
gptkbp:lifespan
|
16 hours
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
endothelin receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:research_areas
|
cardiovascular diseases
pulmonary hypertension
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_measures
|
liver function tests
|
|
gptkbp:side_effect
|
gptkb:anemia
headache
edema
nasopharyngitis
liver function test abnormalities
|
|
gptkbp:strength
|
10 mg
20 mg
|
|
gptkbp:trade
|
gptkb:Opsumit
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:used_for
|
pulmonary arterial hypertension
|
|
gptkbp:bfsParent
|
gptkb:Opsumit
|
|
gptkbp:bfsLayer
|
6
|